ZA200303690B - Imidazolone derivatives for the treatment of viral diseases. - Google Patents

Imidazolone derivatives for the treatment of viral diseases. Download PDF

Info

Publication number: ZA200303690B
Authority: ZA; South Africa
Prior art keywords: alkyl; methyl; dihydro; phenyl; substituted
Prior art date: 2000-11-22

Application number

ZA200303690A

Other languages

English (en)

Inventor

Brian William Dymock

John Herbert Merrett

Martin John Parratt

Philip Stephen Jones

Kevin Edward Burdon Parkes

Daryl Simon Walter

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-22

Filing date

2003-05-13

Publication date

2004-08-13

2003-05-13 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-08-13 Publication of ZA200303690B publication Critical patent/ZA200303690B/en

Links

238000011282 treatment Methods 0.000 title claims description 21
201000010099 disease Diseases 0.000 title claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 19
WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 title description 15
230000003612 virological effect Effects 0.000 title description 6
-1 hydroxy-alky} Chemical group 0.000 claims description 633
150000001875 compounds Chemical class 0.000 claims description 137
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 117
125000001424 substituent group Chemical group 0.000 claims description 106
239000000460 chlorine Substances 0.000 claims description 67
239000001257 hydrogen Substances 0.000 claims description 61
229910052739 hydrogen Inorganic materials 0.000 claims description 61
229910052801 chlorine Inorganic materials 0.000 claims description 59
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 58
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 57
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 57
229910052794 bromium Inorganic materials 0.000 claims description 57
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 53
AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 claims description 50
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 41
125000000623 heterocyclic group Chemical group 0.000 claims description 38
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 37
239000000203 mixture Substances 0.000 claims description 37
125000000217 alkyl group Chemical group 0.000 claims description 34
238000000034 method Methods 0.000 claims description 31
125000003118 aryl group Chemical group 0.000 claims description 28
125000004076 pyridyl group Chemical group 0.000 claims description 27
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 21
150000002148 esters Chemical class 0.000 claims description 19
150000002170 ethers Chemical class 0.000 claims description 18
241000725303 Human immunodeficiency virus Species 0.000 claims description 17
229910052760 oxygen Inorganic materials 0.000 claims description 16
229910052717 sulfur Inorganic materials 0.000 claims description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 11
125000004093 cyano group Chemical group *C#N 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
230000001404 mediated effect Effects 0.000 claims description 11
125000003342 alkenyl group Chemical group 0.000 claims description 10
229910052740 iodine Inorganic materials 0.000 claims description 10
125000005844 heterocyclyloxy group Chemical group 0.000 claims description 9
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000003107 substituted aryl group Chemical group 0.000 claims description 7
125000001309 chloro group Chemical group Cl* 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
230000008569 process Effects 0.000 claims description 5
230000000269 nucleophilic effect Effects 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
KQAJUDIIZSOUOC-UHFFFAOYSA-N 1-methyl-4-phenylsulfanyl-3-propan-2-yl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound C=1C=NC=CC=1CNCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC=CC=C1 KQAJUDIIZSOUOC-UHFFFAOYSA-N 0.000 claims description 2
GELMOEPGYAKMJA-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-1-methyl-5-(phenylmethoxymethyl)-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=CC=1COCC=1N(C)C(=O)N(C(C)C)C=1OC1=CC(Cl)=CC(Cl)=C1 GELMOEPGYAKMJA-UHFFFAOYSA-N 0.000 claims description 2
USNIDRLIIXNZLH-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-5-(hydroxymethyl)-1-methyl-3-propan-2-ylimidazol-2-one Chemical compound CN1C(=O)N(C(C)C)C(SC=2C=C(Cl)C=C(Cl)C=2)=C1CO USNIDRLIIXNZLH-UHFFFAOYSA-N 0.000 claims description 2
UEMAXFKMGOGVDZ-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-5-[(2-hydroxyphenyl)methyl]-1-methyl-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=C(O)C=1CC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 UEMAXFKMGOGVDZ-UHFFFAOYSA-N 0.000 claims description 2
XTQPOASEIPNSHI-UHFFFAOYSA-N 5-benzyl-1-methyl-4-methylsulfanyl-3-propan-2-ylimidazol-2-one Chemical compound CN1C(=O)N(C(C)C)C(SC)=C1CC1=CC=CC=C1 XTQPOASEIPNSHI-UHFFFAOYSA-N 0.000 claims description 2
JFSAWLISEWQWOD-UHFFFAOYSA-N 5-benzyl-4-(3,5-dichlorophenyl)sulfanyl-1-methyl-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=CC=1CC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 JFSAWLISEWQWOD-UHFFFAOYSA-N 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
125000000547 substituted alkyl group Chemical group 0.000 claims description 2
239000000126 substance Substances 0.000 claims 8
UPCCRTUUTXEQKZ-UHFFFAOYSA-N 1,3-dibenzyl-4-(3,5-dichlorophenyl)sulfanyl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound ClC1=CC(Cl)=CC(SC=2N(C(=O)N(CC=3C=CC=CC=3)C=2CNCC=2C=CN=CC=2)CC=2C=CC=CC=2)=C1 UPCCRTUUTXEQKZ-UHFFFAOYSA-N 0.000 claims 1
VRRZFUURQCYQJC-UHFFFAOYSA-N 1-benzyl-4-(3,5-dichlorophenyl)sulfanyl-3-propyl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound C=1C=NC=CC=1CNCC=1N(CC=2C=CC=CC=2)C(=O)N(CCC)C=1SC1=CC(Cl)=CC(Cl)=C1 VRRZFUURQCYQJC-UHFFFAOYSA-N 0.000 claims 1
KCQRKOFYTWSAPC-UHFFFAOYSA-N 1-benzyl-5-(3,5-dichlorophenyl)sulfanyl-4-(1-hydroxyethyl)-3-methylimidazol-2-one Chemical compound C=1C=CC=CC=1CN1C(=O)N(C)C(C(O)C)=C1SC1=CC(Cl)=CC(Cl)=C1 KCQRKOFYTWSAPC-UHFFFAOYSA-N 0.000 claims 1
RYJDQQUYQJLZHC-UHFFFAOYSA-N 1-benzyl-5-(3,5-dichlorophenyl)sulfanyl-4-(hydroxymethyl)-3-methylimidazol-2-one Chemical compound C=1C=CC=CC=1CN1C(=O)N(C)C(CO)=C1SC1=CC(Cl)=CC(Cl)=C1 RYJDQQUYQJLZHC-UHFFFAOYSA-N 0.000 claims 1
KISDUHTWPMAMEB-UHFFFAOYSA-N 1-methyl-3-propan-2-yl-4-propan-2-ylsulfanyl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound CN1C(=O)N(C(C)C)C(SC(C)C)=C1CNCC1=CC=NC=C1 KISDUHTWPMAMEB-UHFFFAOYSA-N 0.000 claims 1
LXKGQDLZEMXESH-UHFFFAOYSA-N 1-methyl-4-(2-methylpropylsulfanyl)-3-propan-2-yl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound CN1C(=O)N(C(C)C)C(SCC(C)C)=C1CNCC1=CC=NC=C1 LXKGQDLZEMXESH-UHFFFAOYSA-N 0.000 claims 1
MYPVRGIHFSSJRF-UHFFFAOYSA-N 3-(5-benzyl-1-methyl-2-oxo-3-propan-2-ylimidazol-4-yl)sulfanylbenzonitrile Chemical compound C=1C=CC=CC=1CC=1N(C)C(=O)N(C(C)C)C=1SC1=CC=CC(C#N)=C1 MYPVRGIHFSSJRF-UHFFFAOYSA-N 0.000 claims 1
YEHHFIDXSIUCQI-UHFFFAOYSA-N 3-[5-(3,5-dichlorophenyl)sulfanyl-3-methyl-2-oxo-1-propan-2-ylimidazol-4-yl]prop-2-enamide Chemical compound CN1C(=O)N(C(C)C)C(SC=2C=C(Cl)C=C(Cl)C=2)=C1C=CC(N)=O YEHHFIDXSIUCQI-UHFFFAOYSA-N 0.000 claims 1
IINNEAQBERGQNV-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-ethyl-3-propan-2-yl-5-(pyridin-4-ylmethyl)imidazol-2-one Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC=1N(C(C)C)C(=O)N(CC)C=1CC1=CC=NC=C1 IINNEAQBERGQNV-UHFFFAOYSA-N 0.000 claims 1
RCIZIRLTPTXVOA-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-methyl-3-phenyl-5-(phenylmethoxymethyl)imidazol-2-one Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC=1N(C=2C=CC=CC=2)C(=O)N(C)C=1COCC1=CC=CC=C1 RCIZIRLTPTXVOA-UHFFFAOYSA-N 0.000 claims 1
VHPYMWDZQDMIBO-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-methyl-3-propan-2-yl-5-(pyridin-3-ylmethoxymethyl)imidazol-2-one Chemical compound C=1C=CN=CC=1COCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 VHPYMWDZQDMIBO-UHFFFAOYSA-N 0.000 claims 1
WFAHJZHPWMHZPY-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-methyl-3-propan-2-yl-5-(pyridin-4-ylmethyl)imidazol-2-one Chemical compound C=1C=NC=CC=1CC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 WFAHJZHPWMHZPY-UHFFFAOYSA-N 0.000 claims 1
XDFQQJPBZQVKQR-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-methyl-3-propan-2-yl-5-(pyridin-4-yloxymethyl)imidazol-2-one Chemical compound C=1C=NC=CC=1OCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 XDFQQJPBZQVKQR-UHFFFAOYSA-N 0.000 claims 1
YNVAZPMOZJXYRH-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-methyl-3-propan-2-yl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound C=1C=NC=CC=1CNCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 YNVAZPMOZJXYRH-UHFFFAOYSA-N 0.000 claims 1
MBRYMALLJUREFI-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-methyl-5-(2-phenylethyl)-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=CC=1CCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 MBRYMALLJUREFI-UHFFFAOYSA-N 0.000 claims 1
DLEZAJAXGJZUHQ-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-methyl-5-(phenylmethoxymethyl)-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=CC=1COCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 DLEZAJAXGJZUHQ-UHFFFAOYSA-N 0.000 claims 1
NMZSFWBJPOJDQU-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-1-methyl-5-[(4-phenylmethoxyphenyl)methoxymethyl]-3-propan-2-ylimidazol-2-one Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1COCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 NMZSFWBJPOJDQU-UHFFFAOYSA-N 0.000 claims 1
JRMPYWFFGORTOO-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-5-(hydroxymethyl)-1-[(4-methoxyphenyl)methyl]-3-propan-2-ylimidazol-2-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(C)C)C(SC=2C=C(Cl)C=C(Cl)C=2)=C1CO JRMPYWFFGORTOO-UHFFFAOYSA-N 0.000 claims 1
WEJVKBXQNVEUFI-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-5-(methoxymethyl)-1-methyl-3-propan-2-ylimidazol-2-one Chemical compound CC(C)N1C(=O)N(C)C(COC)=C1SC1=CC(Cl)=CC(Cl)=C1 WEJVKBXQNVEUFI-UHFFFAOYSA-N 0.000 claims 1
DDCVZMZHUCHLLX-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-5-[hydroxy(phenyl)methyl]-1-methyl-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=CC=1C(O)C=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 DDCVZMZHUCHLLX-UHFFFAOYSA-N 0.000 claims 1
DEQWQFLGUKIWQE-UHFFFAOYSA-N 4-(3-chlorophenyl)sulfanyl-1-methyl-3-propan-2-yl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound C=1C=NC=CC=1CNCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC=CC(Cl)=C1 DEQWQFLGUKIWQE-UHFFFAOYSA-N 0.000 claims 1
HPGUHEDPKZTBBN-UHFFFAOYSA-N 4-benzylsulfanyl-1-methyl-3-propan-2-yl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound C=1C=NC=CC=1CNCC=1N(C)C(=O)N(C(C)C)C=1SCC1=CC=CC=C1 HPGUHEDPKZTBBN-UHFFFAOYSA-N 0.000 claims 1
YAWOMIDJJAGGIU-UHFFFAOYSA-N 4-cyclohexylsulfanyl-1-methyl-3-propan-2-yl-5-[(pyridin-4-ylmethylamino)methyl]imidazol-2-one Chemical compound C=1C=NC=CC=1CNCC=1N(C)C(=O)N(C(C)C)C=1SC1CCCCC1 YAWOMIDJJAGGIU-UHFFFAOYSA-N 0.000 claims 1
PWMMGEBWJGLWSF-UHFFFAOYSA-N 5-(hydroxymethyl)-1-methyl-3-phenyl-4-pyridin-4-ylsulfanylimidazol-2-one Chemical compound C=1C=CC=CC=1N1C(=O)N(C)C(CO)=C1SC1=CC=NC=C1 PWMMGEBWJGLWSF-UHFFFAOYSA-N 0.000 claims 1
AXNWYHITMUZMHL-UHFFFAOYSA-N 5-[(benzylamino)methyl]-1-methyl-4-phenylsulfanyl-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=CC=1CNCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC=CC=C1 AXNWYHITMUZMHL-UHFFFAOYSA-N 0.000 claims 1
PMALHKKGEMHNCF-UHFFFAOYSA-N 5-[(benzylamino)methyl]-4-(3,5-dichlorophenyl)sulfanyl-1-methyl-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=CC=1CNCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(Cl)=CC(Cl)=C1 PMALHKKGEMHNCF-UHFFFAOYSA-N 0.000 claims 1
KCDBYJLTYJFCGH-UHFFFAOYSA-N 5-[(benzylamino)methyl]-4-(3,5-dimethylphenyl)sulfanyl-1-methyl-3-propan-2-ylimidazol-2-one Chemical compound C=1C=CC=CC=1CNCC=1N(C)C(=O)N(C(C)C)C=1SC1=CC(C)=CC(C)=C1 KCDBYJLTYJFCGH-UHFFFAOYSA-N 0.000 claims 1
IOQKNOPKQVLPMK-UHFFFAOYSA-N 5-benzyl-1-methyl-3-propan-2-yl-4-propan-2-ylsulfanylimidazol-2-one Chemical compound CN1C(=O)N(C(C)C)C(SC(C)C)=C1CC1=CC=CC=C1 IOQKNOPKQVLPMK-UHFFFAOYSA-N 0.000 claims 1
OSETZROEBITBOX-UHFFFAOYSA-N 5-benzyl-1-methyl-4-(2-methylpropylsulfanyl)-3-propan-2-ylimidazol-2-one Chemical compound CN1C(=O)N(C(C)C)C(SCC(C)C)=C1CC1=CC=CC=C1 OSETZROEBITBOX-UHFFFAOYSA-N 0.000 claims 1
HAZKJQDNKNFQBW-UHFFFAOYSA-N 5-benzyl-4-(3,5-dichlorophenyl)sulfanyl-1-ethyl-3-propan-2-ylimidazol-2-one Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC=1N(C(C)C)C(=O)N(CC)C=1CC1=CC=CC=C1 HAZKJQDNKNFQBW-UHFFFAOYSA-N 0.000 claims 1
JLMPSZIYQJAPGH-UHFFFAOYSA-N [5-(3,5-dichlorophenyl)sulfanyl-3-methyl-2-oxo-1-propan-2-ylimidazol-4-yl]methyl acetate Chemical compound CN1C(=O)N(C(C)C)C(SC=2C=C(Cl)C=C(Cl)C=2)=C1COC(C)=O JLMPSZIYQJAPGH-UHFFFAOYSA-N 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
238000006243 chemical reaction Methods 0.000 description 127
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 45
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
239000002904 solvent Substances 0.000 description 22
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
150000002431 hydrogen Chemical group 0.000 description 15
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 14
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 14
IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
230000007246 mechanism Effects 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
150000002430 hydrocarbons Chemical group 0.000 description 12
UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
239000003960 organic solvent Substances 0.000 description 11
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 10
125000004432 carbon atom Chemical group C* 0.000 description 10
229960001760 dimethyl sulfoxide Drugs 0.000 description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 9
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 9
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
238000009835 boiling Methods 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
239000003880 polar aprotic solvent Substances 0.000 description 9
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
241000700605 Viruses Species 0.000 description 8
239000002253 acid Substances 0.000 description 8
239000002585 base Substances 0.000 description 8
239000003054 catalyst Substances 0.000 description 8
238000001819 mass spectrum Methods 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 8
239000012312 sodium hydride Substances 0.000 description 8
229910000104 sodium hydride Inorganic materials 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
PXXNTAGJWPJAGM-VCOUNFBDSA-N Decaline Chemical compound C=1([C@@H]2C3)C=C(OC)C(OC)=CC=1OC(C=C1)=CC=C1CCC(=O)O[C@H]3C[C@H]1N2CCCC1 PXXNTAGJWPJAGM-VCOUNFBDSA-N 0.000 description 7
150000001298 alcohols Chemical class 0.000 description 7
229960001701 chloroform Drugs 0.000 description 7
229930195733 hydrocarbon Natural products 0.000 description 7
229940078552 o-xylene Drugs 0.000 description 7
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 7
125000006239 protecting group Chemical group 0.000 description 7
239000000243 solution Substances 0.000 description 7
PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 7
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 6
150000008282 halocarbons Chemical class 0.000 description 6
GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
239000000969 carrier Substances 0.000 description 5
239000003638 chemical reducing agent Substances 0.000 description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
RBWUHCYPXPKMCL-UHFFFAOYSA-N 1-methyl-3-propan-2-ylimidazol-2-one Chemical compound CC(C)N1C=CN(C)C1=O RBWUHCYPXPKMCL-UHFFFAOYSA-N 0.000 description 4
125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 4
125000002856 2-fluorophenylethyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
125000004462 3,4-difluorophenylmethyl group Chemical group FC=1C=C(C=CC1F)C* 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
239000013543 active substance Substances 0.000 description 4
150000001299 aldehydes Chemical class 0.000 description 4
125000003545 alkoxy group Chemical group 0.000 description 4
239000012300 argon atmosphere Substances 0.000 description 4
238000003556 assay Methods 0.000 description 4
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
125000002541 furyl group Chemical group 0.000 description 4
238000005984 hydrogenation reaction Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229910000103 lithium hydride Inorganic materials 0.000 description 4
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 4
239000012299 nitrogen atmosphere Substances 0.000 description 4
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 4
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 3
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 3
CTCCHKSGCBWINA-UHFFFAOYSA-N 2-methoxyethoxy hypofluorite Chemical compound COCCOOF CTCCHKSGCBWINA-UHFFFAOYSA-N 0.000 description 3
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 3
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 3
125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 3
WOJVMOGROOCQLX-UHFFFAOYSA-N 3-(pyridin-4-ylmethyl)-1H-imidazol-2-one Chemical compound O=C1NC=CN1CC1=CC=NC=C1 WOJVMOGROOCQLX-UHFFFAOYSA-N 0.000 description 3
PXHFWPOPKVWXQT-UHFFFAOYSA-N 3-methyl-1h-imidazol-2-one Chemical compound CN1C=CN=C1O PXHFWPOPKVWXQT-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
239000001828 Gelatine Substances 0.000 description 3
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000003443 antiviral agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
DWRDBJCTLDOPFZ-UHFFFAOYSA-N imidazole-2,4-dione Chemical class O=C1NC(=O)N=C1 DWRDBJCTLDOPFZ-UHFFFAOYSA-N 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
125000006384 methylpyridyl group Chemical group 0.000 description 3
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 description 2
MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 2
125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 2
125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 2
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 2
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 2
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
YANWIOIEGWOZGP-UHFFFAOYSA-N 3-propan-2-yl-1h-imidazol-2-one Chemical compound CC(C)N1C=CNC1=O YANWIOIEGWOZGP-UHFFFAOYSA-N 0.000 description 2
AKPSLMUFDIXDJJ-UHFFFAOYSA-N 4-(bromomethyl)-1,2-dimethoxybenzene Chemical compound COC1=CC=C(CBr)C=C1OC AKPSLMUFDIXDJJ-UHFFFAOYSA-N 0.000 description 2
WWHJLVMBXXXUFO-UHFFFAOYSA-N 4-(chloromethyl)-1,2-dimethoxybenzene Chemical compound COC1=CC=C(CCl)C=C1OC WWHJLVMBXXXUFO-UHFFFAOYSA-N 0.000 description 2
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
CXBMWVZWUNNNJW-UHFFFAOYSA-N 5-(dimethylaminomethylidene)-1-methyl-3-propan-2-ylimidazolidine-2,4-dione Chemical compound CC(C)N1C(=O)N(C)C(=CN(C)C)C1=O CXBMWVZWUNNNJW-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
208000030852 Parasitic disease Diseases 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
239000000920 calcium hydroxide Substances 0.000 description 2
229910001861 calcium hydroxide Inorganic materials 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
125000003636 chemical group Chemical group 0.000 description 2
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
125000005805 dimethoxy phenyl group Chemical group 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000008298 dragée Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003925 fat Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
230000003463 hyperproliferative effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000011630 iodine Substances 0.000 description 2
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
239000001095 magnesium carbonate Substances 0.000 description 2
229910000021 magnesium carbonate Inorganic materials 0.000 description 2
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
239000000347 magnesium hydroxide Substances 0.000 description 2
229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
239000001630 malic acid Substances 0.000 description 2
235000011090 malic acid Nutrition 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000003223 protective agent Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
238000002976 reverse transcriptase assay Methods 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000001117 sulphuric acid Substances 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
201000011531 vascular cancer Diseases 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
239000001993 wax Substances 0.000 description 2
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
FFJKWLCYNCACSN-UHFFFAOYSA-N 1-(methoxymethyl)-3-methylimidazol-2-one Chemical compound COCN1C(N(C=C1)C)=O FFJKWLCYNCACSN-UHFFFAOYSA-N 0.000 description 1
SDXZEGKIWVOOFU-UHFFFAOYSA-N 1-methyl-3-phenylimidazol-2-one Chemical compound O=C1N(C)C=CN1C1=CC=CC=C1 SDXZEGKIWVOOFU-UHFFFAOYSA-N 0.000 description 1
IFUCLLDLONIGJB-UHFFFAOYSA-N 1-methyl-3-propan-2-ylimidazolidine-2,4-dione Chemical compound CC(C)N1C(=O)CN(C)C1=O IFUCLLDLONIGJB-UHFFFAOYSA-N 0.000 description 1
GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 description 1
125000006183 2,4-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])*)C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000006184 2,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
ZFQARABCLRPYPB-UHFFFAOYSA-N 2-[methyl(propan-2-ylcarbamoyl)amino]acetic acid Chemical compound CC(C)NC(=O)N(C)CC(O)=O ZFQARABCLRPYPB-UHFFFAOYSA-N 0.000 description 1
HZDLKNOGBSMKRN-UHFFFAOYSA-N 2-amino-5-[[5-oxo-4-(2,3,4-trihydroxybutyl)-1,4-dihydroimidazol-2-yl]amino]pentanoic acid Chemical compound OC(=O)C(N)CCCNC1=NC(CC(O)C(O)CO)C(=O)N1 HZDLKNOGBSMKRN-UHFFFAOYSA-N 0.000 description 1
125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
125000006185 3,4-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
WRXIPCQPHZMXOO-UHFFFAOYSA-N 3,5-dichlorobenzenethiol Chemical compound SC1=CC(Cl)=CC(Cl)=C1 WRXIPCQPHZMXOO-UHFFFAOYSA-N 0.000 description 1
125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 1
125000006186 3,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C([H])=C1C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
GCFVMXFGGJMDJI-UHFFFAOYSA-N 3-(pyridin-4-yloxymethyl)-1H-imidazol-2-one Chemical compound N1=CC=C(C=C1)OCN1C(NC=C1)=O GCFVMXFGGJMDJI-UHFFFAOYSA-N 0.000 description 1
125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 1
LITSFUAQSGPXMJ-UHFFFAOYSA-N 3-ethenyl-1h-imidazol-2-one Chemical compound OC1=NC=CN1C=C LITSFUAQSGPXMJ-UHFFFAOYSA-N 0.000 description 1
125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
125000006291 3-hydroxybenzyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
ZZNMRBGELWVJND-UHFFFAOYSA-N 3-phenyl-1h-imidazol-2-one Chemical compound O=C1NC=CN1C1=CC=CC=C1 ZZNMRBGELWVJND-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 1
RPCXXXYDFJIVQU-UHFFFAOYSA-N 5-(dimethylaminomethylidene)imidazolidine-2,4-dione Chemical class CN(C)C=C1NC(=O)NC1=O RPCXXXYDFJIVQU-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
244000257727 Allium fistulosum Species 0.000 description 1
235000008553 Allium fistulosum Nutrition 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007818 Grignard reagent Substances 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
239000012448 Lithium borohydride Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 1
108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
102000007124 Tachykinin Receptors Human genes 0.000 description 1
108010072901 Tachykinin Receptors Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
238000007239 Wittig reaction Methods 0.000 description 1
DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000002137 anti-vascular effect Effects 0.000 description 1
238000002832 anti-viral assay Methods 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
229910001863 barium hydroxide Inorganic materials 0.000 description 1
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000006380 bromopyridyl group Chemical group 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 1
239000012320 chlorinating reagent Substances 0.000 description 1
125000006378 chloropyridyl group Chemical group 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000006392 deoxygenation reaction Methods 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
125000006285 dibromobenzyl group Chemical group 0.000 description 1
125000006286 dichlorobenzyl group Chemical group 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
229960003804 efavirenz Drugs 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000006379 fluoropyridyl group Chemical group 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
150000003948 formamides Chemical class 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002332 glycine derivatives Chemical class 0.000 description 1
150000004795 grignard reagents Chemical class 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
125000006301 indolyl methyl group Chemical group 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
DCNUQRBLZWSGAV-UHFFFAOYSA-N n,n-diphenylformamide Chemical compound C=1C=CC=CC=1N(C=O)C1=CC=CC=C1 DCNUQRBLZWSGAV-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
125000006504 o-cyanobenzyl group Chemical group [H]C1=C([H])C(C#N)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000004344 phenylpropyl group Chemical group 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
ZHOVAWFVVBWEGQ-UHFFFAOYSA-N tripropylsilane Chemical compound CCC[SiH](CCC)CCC ZHOVAWFVVBWEGQ-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
206010055031 vascular neoplasm Diseases 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200303690A 2000-11-22 2003-05-13 Imidazolone derivatives for the treatment of viral diseases. ZA200303690B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0028484.4A GB0028484D0 (en)	2000-11-22	2000-11-22	Imidazolone derivatives for the treatment of viral diseases

Publications (1)

Publication Number	Publication Date
ZA200303690B true ZA200303690B (en)	2004-08-13

Family

ID=9903671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200303690A ZA200303690B (en)	2000-11-22	2003-05-13	Imidazolone derivatives for the treatment of viral diseases.

Country Status (20)

Country	Link
US (1)	US6518293B2 (de)
EP (1)	EP1341766B1 (de)
JP (1)	JP2004514672A (de)
KR (1)	KR100528760B1 (de)
CN (1)	CN1633417A (de)
AR (1)	AR035372A1 (de)
AT (1)	ATE307805T1 (de)
AU (2)	AU2002221842B2 (de)
BR (1)	BR0115476A (de)
CA (1)	CA2428461A1 (de)
DE (1)	DE60114448T2 (de)
DK (1)	DK1341766T3 (de)
ES (1)	ES2251529T3 (de)
GB (1)	GB0028484D0 (de)
MX (1)	MXPA03004454A (de)
PA (1)	PA8533301A1 (de)
PE (1)	PE20020636A1 (de)
UY (1)	UY27035A1 (de)
WO (1)	WO2002042279A1 (de)
ZA (1)	ZA200303690B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200423930A (en) *	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
WO2005100322A1 (en) *	2004-04-14	2005-10-27	Pfizer Limited	Sulphur-linked imidazole compounds for the treament of hiv
CA2592909A1 (en) *	2005-01-06	2006-07-13	Pfizer Limited	Imidazole derivatives as enzyme reverse transcriptase modulators
WO2008085008A1 (en) *	2007-01-11	2008-07-17	Mogam Biotechnology Research Institute	T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
KR101110120B1 (ko) *	2009-10-28	2012-01-31	주식회사 케이아이테크놀로지	표지판 완충장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4345936A (en) *	1981-10-05	1982-08-24	Eli Lilly And Company	Imidazoles, compositions and herbicidal method
TW235963B (de)	1992-01-16	1994-12-11	Shionogi & Co
EP0627423A4 (de)	1992-01-22	1995-02-15	Nissan Chemical Ind Ltd	Substituierte pyrazol-derivate und bakterizide für landwirtschaft und gartenbau.
GB9222262D0 (en)	1992-10-23	1992-12-09	Merck Sharp & Dohme	Therapeutic agents
US5612636A (en) *	1995-01-19	1997-03-18	Texas Instruments Incorporated	Short circuit power optimization for CMOS circuits
US5612363A (en)	1995-06-02	1997-03-18	Berlex Laboratories, Inc.	N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US6046331A (en) *	1998-12-17	2000-04-04	Synaptic Pharmaceutical Corporation	Imidazolones and their use in treating benign prostatic hyperplasia and other disorders

2000
- 2000-11-22 GB GBGB0028484.4A patent/GB0028484D0/en not_active Ceased
2001
- 2001-11-06 US US09/993,848 patent/US6518293B2/en not_active Expired - Fee Related
- 2001-11-12 CN CNA018193528A patent/CN1633417A/zh active Pending
- 2001-11-12 AT AT01997479T patent/ATE307805T1/de not_active IP Right Cessation
- 2001-11-12 DK DK01997479T patent/DK1341766T3/da active
- 2001-11-12 AU AU2002221842A patent/AU2002221842B2/en not_active Ceased
- 2001-11-12 AU AU2184202A patent/AU2184202A/xx active Pending
- 2001-11-12 CA CA002428461A patent/CA2428461A1/en not_active Abandoned
- 2001-11-12 MX MXPA03004454A patent/MXPA03004454A/es active IP Right Grant
- 2001-11-12 BR BR0115476-1A patent/BR0115476A/pt not_active IP Right Cessation
- 2001-11-12 WO PCT/EP2001/013069 patent/WO2002042279A1/en not_active Ceased
- 2001-11-12 JP JP2002544414A patent/JP2004514672A/ja active Pending
- 2001-11-12 DE DE60114448T patent/DE60114448T2/de not_active Expired - Fee Related
- 2001-11-12 ES ES01997479T patent/ES2251529T3/es not_active Expired - Lifetime
- 2001-11-12 EP EP01997479A patent/EP1341766B1/de not_active Expired - Lifetime
- 2001-11-12 KR KR10-2003-7006881A patent/KR100528760B1/ko not_active Expired - Fee Related
- 2001-11-20 PE PE2001001158A patent/PE20020636A1/es not_active Application Discontinuation
- 2001-11-21 PA PA20018533301A patent/PA8533301A1/es unknown
- 2001-11-21 UY UY27035A patent/UY27035A1/es not_active Application Discontinuation
- 2001-11-21 AR ARP010105422A patent/AR035372A1/es not_active Application Discontinuation
2003
- 2003-05-13 ZA ZA200303690A patent/ZA200303690B/en unknown

Also Published As

Publication number	Publication date
CA2428461A1 (en)	2002-05-30
EP1341766A1 (de)	2003-09-10
EP1341766B1 (de)	2005-10-26
BR0115476A (pt)	2003-08-19
UY27035A1 (es)	2002-06-20
KR100528760B1 (ko)	2005-11-15
PE20020636A1 (es)	2002-07-18
WO2002042279A1 (en)	2002-05-30
ES2251529T3 (es)	2006-05-01
CN1633417A (zh)	2005-06-29
AU2184202A (en)	2002-06-03
PA8533301A1 (es)	2002-08-26
KR20030060951A (ko)	2003-07-16
AR035372A1 (es)	2004-05-12
AU2002221842B2 (en)	2007-08-23
DK1341766T3 (da)	2006-02-20
DE60114448T2 (de)	2006-07-06
US6518293B2 (en)	2003-02-11
JP2004514672A (ja)	2004-05-20
ATE307805T1 (de)	2005-11-15
DE60114448D1 (de)	2005-12-01
MXPA03004454A (es)	2003-08-19
GB0028484D0 (en)	2001-01-10
US20020107272A1 (en)	2002-08-08

Publication	Publication Date	Title
US10857139B2 (en)	2020-12-08	Substituted diazaspiroalkanes as androgen receptor modulators
EP3567035B1 (de)	2022-06-01	N-substituierten 2,5-dioxo-azolin-verbindungen mit krebshemmender wirkung
US12187682B2 (en)	2025-01-07	MCT4 inhibitors for treating disease
SU1400508A3 (ru)	1988-05-30	Способ получени производных арилтиазолов
PT1024138E (pt)	2007-08-01	Derivados de pirazole
JP2000516619A (ja)	2000-12-12	Ｉｌ―８レセプターアンタゴニスト
AU1998501A (en)	2001-06-06	5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
EP3927700A1 (de)	2021-12-29	Kinaseinhibitoren
PT1401826E (pt)	2007-06-19	Derivados de pirazole utilizados como inibidores da transcriptase inversa do vih
US20020032221A1 (en)	2002-03-14	Pyrrole derivatives
ZA200303690B (en)	2004-08-13	Imidazolone derivatives for the treatment of viral diseases.
US20220089555A1 (en)	2022-03-24	N-benzyl-n-arylsulfonamide derivative and preparation and use thereof
KR960003326B1 (ko)	1996-03-08	발작성 질환 치료용 약제학적 조성물
AU2002221842A1 (en)	2002-08-08	Imidazolone derivatives for the treatment of viral diseases
WO1997046555A1 (en)	1997-12-11	Imidazole-substituted quinoxalinedione derivatives
TW202515538A (zh)	2025-04-16	氟烷氧基伸烷基－二氫咪唑并〔５，１－ｄ〕四嗪酮化合物及相關化合物以及其在治療醫學疾患中之用途
HK40066026A (en)	2022-08-12	Mct4 inhibitors for treating disease
HK1253239B (en)	2022-05-13	Mct4 inhibitors for treating disease
HK1139143B (en)	2017-04-28	Compounds with anti-cancer activity
NZ314407A (en)	1998-03-25	2-amino-benzenesulphonic acid derivatives